Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31092573 | 0.83 | MEN1 (0.51) | AAK1MMP13MAPTKMT2AMAPK1 | |
| SCHEMBL27132340 | 0.83 | MTOR (0.49) | AAK1MMP13MAPTKMT2AATM | |
| SCHEMBL27153076 | 0.83 | MEN1 (0.48) | MAPTKMT2AATMMTORCTSL | |
| SCHEMBL27153075 | 0.83 | MEN1 (0.48) | MAPTKMT2AATMMTORCTSL | |
| SCHEMBL6889868 | 0.81 | AAK1 (0.53) | AAK1MMP13RENCTSLCTSB | |
| SCHEMBL6889863 | 0.81 | AAK1 (0.53) | AAK1MMP13RENCTSLCTSB | |
| SCHEMBL30807716 | 0.81 | MTOR (0.47) | AAK1MMP13MAPTKMT2AATM | |
| SCHEMBL25288617 | 0.79 | CTSK (0.53) | AAK1RENCTSLCTSBCTSS | |
| SCHEMBL29052582 | 0.79 | CTSK (0.50) | AAK1RENCTSLCTSBCTSS | |
| SCHEMBL31512916 | 0.79 | REN (0.59) | AAK1MMP13RENMAPK1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240325409-A1 | Fused Heterotetracyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2024182271-A1 | FUSED HETEROTETRACYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | AAK1 4533/4885MMP13 2698/4885MAPT 4391/4885 |
| US-20240325409-A1 | Fused Heterotetracyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | AAK1 4460/4885MMP13 2169/4885MAPT 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.